0001209191-20-050607.txt : 20200915
0001209191-20-050607.hdr.sgml : 20200915
20200915205423
ACCESSION NUMBER: 0001209191-20-050607
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20200915
FILED AS OF DATE: 20200915
DATE AS OF CHANGE: 20200915
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Adelman Robert J
CENTRAL INDEX KEY: 0001329161
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39512
FILM NUMBER: 201177179
MAIL ADDRESS:
STREET 1: 1700 OWENS STREET
STREET 2: SUITE 595
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94158
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Metacrine, Inc.
CENTRAL INDEX KEY: 0001634379
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 472297384
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3985 SORRENTO VALLEY BLVD., SUITE C
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-369-7800
MAIL ADDRESS:
STREET 1: 3985 SORRENTO VALLEY BLVD., SUITE C
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
3
1
doc3.xml
FORM 3 SUBMISSION
X0206
3
2020-09-15
0
0001634379
Metacrine, Inc.
MTCR
0001329161
Adelman Robert J
C/O METACRINE, INC.
3985 SORRENTO VALLEY BLVD., SUITE C
SAN DIEGO
CA
92121
1
0
1
0
Series A Convertible Preferred Stock
Common Stock
1960784
I
See footnote
Series B Convertible Preferred Stock
Common Stock
472250
I
See footnote
Series C Convertible Preferred Stock
Common Stock
396089
I
See footnote
Every 5.1 shares of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the "Preferred Stock") are convertible into 1 share of Common Stock upon the closing of the Issuer's initial public offering. Share numbers give effect to such conversion. The Preferred Stock has no expiration date.
The shares are held by venBio Global Strategic Fund, L.P. venBio Global Strategic GP, L.P. is the general partner of venBio Global Strategic Fund, L.P. and venBio Global Strategic GP, Ltd. is the general partner of venBio Global Strategic GP, L.P. Robert Adelman is a director of venBio Global Strategic GP, Ltd. Each of venBio Global Strategic GP, L.P., venBio Global Strategic GP, Ltd. and Mr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein.
See Power of Attorney attached as Exhibit 24.1.
Robert Adelman, by: /s/ David Pezeshki, Attorney-in-fact
2020-09-15
EX-24.3_937270
2
poa.txt
POA DOCUMENT
Exhibit 24.1
POWER OF ATTORNEY
KNOW ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and
appoints David Pezeshki his true and lawful attorney-in-fact, with full power of
substitution, to sign any and all instruments, certificates and documents that
may be necessary, desirable or appropriate to be executed on behalf of himself
as an individual or in his capacity as a direct or indirect general partner,
director, officer, member or manager of any partnership, corporation or limited
liability company, pursuant to section 13 or 16 of the Securities Exchange Act
of 1934, as amended (the "Exchange Act"), and any and all regulations
promulgated thereunder, and to file the same, with all exhibits thereto, and any
other documents in connection therewith, with the Securities and Exchange
Commission, and with any other entity when and if such is mandated by the
Exchange Act or by the Financial Industry Regulatory Authority, granting unto
said attorney-in-fact full power and authority to do and perform each and every
act and thing necessary, desirable or appropriate, fully to all intents and
purposes as he might or could do in person, thereby ratifying and confirming all
that said attorney-in-fact, or his substitutes, may lawfully do or cause to be
done by virtue hereof.
IN WITNESS WHEREOF, this Power of Attorney has been signed as of the 10th day of
February, 2017.
/s/ Robert Adelman
Robert Adelman
/s/ Corey Goodman
Corey Goodman